



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/981,239	10/18/2001	Rita De Santis	2818-64	6035

7590 02/26/2002

NIXON & VANDERHYE P.C.  
8th Floor  
1100 North Glebe Rd.  
Arlington, VA 22201-4714

[REDACTED] EXAMINER

QIAN, CELINE X

[REDACTED] ART UNIT

[REDACTED] PAPER NUMBER

1636

DATE MAILED: 02/26/2002

3

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.	DE SANTIS, RITA
09/981,239	
Examiner	Art Unit
Celine Qian	1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

1) Responsive to communication(s) filed on \_\_\_\_\_.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

4) Claim(s) 1-31 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) \_\_\_\_\_ is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) 1-31 are subject to restriction and/or election requirement.

### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some \* c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

### Attachment(s)

1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_.

4) Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_.  
 5) Notice of Informal Patent Application (PTO-152)  
 6) Other: \_\_\_\_\_

## DETAILED ACTION

Claims 1-31 are pending in the application.

### *Election/Restrictions*

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-18, drawn to a method for generating antigen presenting cells, and cells generated by said method, classified in class 435, subclass 2 and 325.
- II. Claims 19-23, drawn to a method of using antigen-presenting cells to prevent and treat malignancies, classified in class 435, subclass 325.
- III. Claim 24, drawn to a pool of antigen for use as cancer vaccine, classified in class 424, subclass 184.1.
- IV. Claims 25-29, drawn to a cancer vaccine comprising antigen-presenting cells, classified in class 435, subclass 325.
- V. Claim 30, drawn to a method of use antigen presenting cells for generating effector immune cells, classified in class 435, subclass 325.
- VI. Claim 31, drawn to an article of manufacture comprising a cancer vaccine comprising antigen presenting cells and a pharmaceutical composition suitable for systemic administration of a hypomethylating agent, classified in class 435, subclass 325.

The inventions are distinct, each from the other for the following reasons:

Inventions of Groups I, II, V and Groups III, IV, VI are patentably distinct because the inventions are drawn to materially different compositions and methods that are not directly

Art Unit: 1636

related. The methods of Groups I, II and V do not require the antigen of Group III, vaccine of Group IV or the article of manufacture of Group VI. Therefore, the inventions of Groups I, II, V are patentably distinct from the inventions of Groups III, IV and VI.

Inventions of Groups I, II and V are patentably distinct from each other because the inventions are drawn methods that require different starting material and modes of operation. Each method requires different method steps. Therefore, the inventions of Groups I, II and V are patentably distinct.

Inventions of Groups III, IV and VI are patentably distinct from each other because the inventions are drawn to materially different compositions. The antigen of Group III, the vaccine of Group IV and the article of manufacture of Group VI are chemically, biologically and functionally distinct from each other. Therefore, the inventions of Groups III, IV and VI are patentably distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian whose telephone number is 703-306-0283. The examiner can normally be reached on 9:00-5:30 M-F.

Art Unit: 1636

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel can be reached on 703-305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Celine Qian, Ph.D.  
February 22, 2002

*Remy Yucel*  
**REMY YUCEL, PH.D**  
**SUPERVISORY PATENT EXAMINER**  
**TECHNOLOGY CENTER 1600**